摘要
目的探讨瑞舒伐他汀钙对冠心病患者血脂水平及颈动脉粥样硬化斑块的影响。方法 42例冠心病合并颈动脉粥样硬化斑块的患者给予口服瑞舒伐他汀钙片,10 mg/d,疗程12个月,测定患者治疗前及治疗6、12个月时血浆总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平,彩色多普勒超声测定颈动脉内膜中层厚度(IMT)及计算颈动脉斑块积分。结果治疗6个月时,患者TC、TG及LDL-C水平与治疗前比较明显下降,而HDL-C水平明显升高,差异均有统计学意义(P<0.05),治疗12个月后,与治疗6个月时比较差异有统计学意义(P<0.05);治疗6个月时颈动脉IMT与治疗前比较显著减轻,颈动脉粥样斑块积分明显下降,差异有统计学意义(P<0.05),治疗12个月时与治疗6个月时比较差异有统计学意义(P<0.05)。结论冠心病患者口服瑞舒伐他汀钙可显著改善其血脂水平及动脉粥样硬化程度。
Objective To explore the effects of Rosuvastatin calcium on blood lipids and carotid atherosclerotic plaques in patients with coronary heart disease （CHD）. Methods Forty-two patients with CHD were treated with Rosuvastatin calcium （ 10 mg once daily） for 12 months. The levels of total cholesterol （TC）, triglyceride （TG）, low-density lipoprotein cholesterol （LDL-C） and high-density lipoprotein cholesterol（HDL-C） were detected before treatment and 6 and 12 months later after treatment, and the ca- rotid intima-media thickness （IMT） was measured and the score of carotid plaque was calculated. Results The levels of TC, TG and LDL-C decreased and the HDL-C increased after 6 months＇ treatment （ P 〈 0.05 ）. IMT and carotid plaque score decreased after 6 months＇ treatment （P 〈0.05）. The above changes were more significant after 12 months＇ treatment （P 〈0.05）. Conclusion Rosuvastatin calcium can improve lipid level and atherosclerosis in patients with CHD.
出处
《临床军医杂志》
CAS
2013年第8期777-779,共3页
Clinical Journal of Medical Officers
关键词
冠心病
颈动脉
粥样硬化斑块
瑞舒伐他汀钙
coronary heart disease
carotid
atherosclerotic plaque
Rosuvastatin
作者简介
作者简介：於宏（1969-），女，安徽滁州人，主治医师，医学硕士，目前主要从事内科临床及研究工作
